BCR and B-cell chronic lymphocytic leukemia: Promising results have been obtained by targeting different players in BCR signaling such as PKCβ or MALT1 whose inhibition is effective in ABC-DLBCL, MCL, and naïve as well as ibrutinib-resistant CLL (190–193).